Sean Wu is an associate in the Shanghai office of Latham & Watkins and a member of the Litigation & Trial Department.
Mr. Wu’s practice focuses on advising clients on internal investigations, due diligence, and compliance programs, in connection with FCPA, anti-corruption / anti-bribery, and trade compliance matters in China.
Mr. Wu has represented and conducted internal investigations for multinational clients across different industries, including pharmaceutical, medical, finance, manufacturing, online retailing, internet and technology, and consulting.
Prior to joining Latham, Mr. Wu worked in the Beijing office of an international law firm.
Mr. Wu’s experience includes:
- Conducting internal investigations for the audit committee of a US-listed China-based pharmaceutical company, including representing it before the US DOJ, SEC, and Nasdaq, in connection with potential FCPA violations
- Conducting an internal investigation for a multinational finance institute, in connection with export control / financial sanction matters
- Conducting an internal investigation for a multinational equipment manufacturer, in connection with trade restriction matters
- Conducting internal investigations for multinational companies, in connection with fraud and anti-bribery matters
- Performing anti-corruption / anti-bribery compliance due diligence for multinational clients
- Advising clients on developing and implementing anti-corruption compliance policies and procedures
- Conducting an FCPA investigation for a multinational pharmaceutical company after the Chinese government investigated the company’s violations of the People's Republic of China (PRC) anti-bribery laws, including advising the client on disclosures to the US DOJ and SEC*
- Conducting internal investigations for a multinational technology company’s Asia Pacific and Japan offices, in connection with various matters including conflict of interest, financial fraud, anti-bribery, and other company procedural violations*
- Conducting multiple internal investigations for a multinational pharmaceutical company in connection with financial fraud, safety regulation, and anti-bribery matters*
- Conducting an internal investigation for a US-listed China-based consulting company in connection with fraud matters*
- Representing a US-listed medical device company in connection with regulatory inquiries from Chinese and overseas regulators*
*Matter handled prior to joining Latham